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ABSTRACT 
Objective: Risperidone is an atypical antipsychotic drug used to treat schizophrenia; however it suffers from a poor aqueous solubility, which 
delays its onset of action. Therefore, the purpose of the present study is to utilize the nanotechnology to formulate nanoparticles that enhance the 
dissolution and hence the bioavailability of risperidone.  
Methods: Nanosuspensions were prepared by nano precipitation method in the presence of selected stabilizers at different concentrations. The 
nanosuspensions were evaluated for their particle size, zeta potential, drug content and In vitro drug dissolution. The selected formula was freeze 
dried and characterized by scanning electron microscopy (SEM), fourier transforms infrared spectroscopy (FTIR), differential scanning calorimetry 
(DSC), X-ray diffractometry studies (XRD) and pharmacokinetic study. 
Results: The in vitro dissolution showed higher drug release compared to the pure drug. The optimum formula has an average particle size of 
215.56±12.65 nm and zeta potential of-19.84±2.55mV. The bioavailability parameters in the rabbits were enhanced by 2 folds when compared with 
the marketed tablets (Risperidal®). 
Conclusion: Nanoprecipitation method was successfully employed to produce stable risperidone nanosuspension by using the proper stabilizer 
(pluronic F 127). Risperidone nanoparticles may be a promising formula that improves the dissolution and hence oral bioavailability of poorly 
water soluble risperidone.  
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INTRODUCTION  
Risperidone, a novel benzisoxazole-type atypical antipsychotic, is 
effective in the treatment of positive as well as negative symptoms of 
schizophrenia and has a low incidence of extrapyramidal side effects 
[1-3]. It is approved by the FDA for the treatment of schizophrenia 
bipolar disorder and irritability in children and adolescents ages [4]. 
Risperidone is practically insoluble in water, freely soluble in 
methylene chloride, and soluble in methanol [5, 6]. Nanosuspension 
is an is an efficient and intelligent approach used to deliver water-
insoluble drugs where the drug is reduced to the submicron range as 
the saturation solubility and the surface area available for 
dissolution increased thereby increasing its dissolution rate and 
hence its bioavailability [7, 8]. Stabilizer plays an important role in 
the formulation of nanosuspensions. In the absence of an 
appropriate stabilizer, the high surface energy of nano-sized 
particles can induce agglomeration of articles. The main functions of a 
stabilizer are wetting the drug particles thoroughly, and preventing 
Ostwald’s ripening [9]. Nanoprecipitation method presents numerous 
advantages, in that it is a straightforward technique, rapid and easy to 
perform. In this method, the drug is dissolved in an organic solvent 
such as acetone, acetonitrile, methanol or ethyl acetate. The organic 
solvent is evaporated either by reducing the pressure or by continuous 
stirring. Particle size was found to be influenced by the type of 
stabilizer, concentrations of stabilizer, and homogenizer speed [10]. In 
the present work, nanosuspension is prepared by nanoprecipitation 
method in which drug is dissolved in a solvent, which is then added to 
non-solvent that cause precipitation of the fine drug particle and the 
system is stabilized by polymer and surfactant. The objective of this 
work was to formulate and optimize risperidone nanoparticles.  
MATERIALS AND METHODS 
Materials  
Risperidone (Janssen-Cilag, Egypt), polyvinyl pyrrolidine (PVP K30), 
was kindly supplied by EPICO pharmaceutical company, Egypt. 
Pluronic F127 by Sigma-Aldrich, Inc., Germany. Tween 80 
(Polyoxyethylene sorbitan monolaurate,) and Ethyl alcohol 95% V/V 
by EL-Nasr pharmaceutical chemical CO. (Egypt). Every additional 
chemical or reagent was of analytical grade or better. 
Methods 
Preparation of risperidone nanosuspensions 
Nanosuspensions were developed according to the nanoprecipitation 
method [11-14]. In brief, risperidone (20 mg) and two different 
stabilizers (Pluronic F 127, PVP K30) were dissolved in an organic 
solvent (10 ml of 95% ethanol) to form a series of organic solutions at 
room temperature (25±1 °C) containing different concentrations of 
stabilizers. Deionized water containing a surfactant (1% tween 80), 
which acts as the antisolvent system was cooled at low temperature 
(below 4 °C). This was followed by adding the organic solution into 
aqueous solution at a very slow rate (0.5 ml/min) by the help of syringe, 
under high-speed mechanical agitation of 8000 rpm using Probe 
sonicator (model VC 505) for 10 min to get the desired nano suspension. 
The cooling was maintained throughout the process using an ice-water 
bath which controlled the precipitation rate. The batches were prepared 
according to the formulation design (table 1). The suspensions were kept 
under vacuum at 25 ° C for 2 h to remove organic solvents. 
Characterization of the prepared nanosuspension 
Particle size and poly dispersity Index 
The prepared risperidone nanosuspensions were measured by 
Photon Correlation Spectroscopy (PCS) using a Zetasizer Nano ZS-90 
instrument. In order to analyse, an aliquot of the nanosuspension 
was diluted before the measurement. Measurements were 
performed in triplicate at 90 ° scattering angle and at 25 °C. 
Determination of zeta potential 
The zeta potential of the nanosuspensions was measured by using 
an additional electrode in the same instrument used for particle size 
analysis (Malvern Zetasizer). Samples of formulations were diluted 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 5, 2016 
Kharshoum et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 5, 136-142 
 
137 
with water and placed in the electrophoretic cell as the 
electrophoretic mobility was converted to zeta potential using the 
Smoluchowski equation [15]. Each sample was measured three 
times at 25 °C and average values were calculated. 
 
Table 1: The composition of the prepared formulae of risperidone nanosuspension 
Surfactant (tween 80) Stabilizer concentration Stabilizer type Water Ethanol Drug Formula no. 
1% w/v 0.1%w/v Pluronic F127 100 ml 10 ml 20 mg F1 
1% w/v 0.4%w/v Pluronic F127 100 ml 10 ml 20 mg F2 
1% w/v 0.6%w/v Pluronic F127 100 ml 10 ml 20 mg F3 
1% w/v 0.8%w/v Pluronic F127 100 ml 10 ml 20 mg F4 
1% w/v 0.1%w/v PVP* K30 100 ml 10 ml 20 mg F5 
1% w/v 0.4%w/v PVP K30 100 ml 10 ml 20 mg F6 
1% w/v 0.6%w/v PVP K30 100 ml 10 ml 20 mg F7 
1% w/v 0.8%w/v PVP K30 100 ml 10 ml 20 mg F8 
*PVP K30 (Polyvinyl pyrrolidine K30) 
 
Determination of the total drug content 
The prepared formulae were assayed individually for the content of 
the drug as follows: An aliquot (0.5 ml) was dissolved in 10 ml 
phosphate buffer (pH 7.4) and filtered through 0.45 μm filter paper. 
The drug concentration was analyzed using UV spectrophotometer 
(UV-1600, Shimadzu, Japan) at λmax 276.8 nm after proper dilution 
using phosphate buffer as a blank. Total drug content (TDC) and 
%TDC were calculated from the following equations:  
TDC = [Vol. total/Vol. Aliquot] × Drug amount in aliquot × 100 
(Equation 1) 
% TDC = [ TDC/TAD] × 100 (Equation 2) 
Where, Vol. Total/Vol. Aliquot is the ratio of total Nanosuspension 
volume to the volume of an aliquot taken and the total amount of 
drug is taken for the formulation of nanosuspension, TAD (total 
added drug) [16]. 
In vitro dissolution studies of the prepared formulae 
The dissolution of each of the prepared formulae were studied under 
sink conditions then compared to the raw drug dissolution profile. 
Accurately weighed bulk drug and nanosuspensions (all equivalent 
to 2 mg of risperidone) were dissolved in (10 ml) phosphate buffer 
(pH7.4). The particles were added to a dialysis bag (Mw cut-off = 
12,000Da). Following this, the formulae were released in a beaker 
containing phosphate buffered (500 ml) and stirred at a constant 
speed of (200 rpm) by a magnetic stirrer at 37±0.5 °C. Samples (5 
ml) were withdrawn and replaced with a fresh medium at 5, 10, 15, 
20, 30 and 45 min, filtered and measured spectrophotometrically at 
λmax 276.8 nm. The experiments were done in triplicates for each of 
the selected formula. The drug release kinetics of the prepared 
formulae was performed for zero-order, first-order and Higuchi by 
using Microsoft Excel Add-InsDD Solver. 
Lyophilization of selected nanosuspensions 
In order to remove the water from the nanoparticle, freeze drying 
(also known as lyophilization) is most commonly used [17, 18]. The 
selected nanosuspension was frozen and lyophilized using a freeze 
dryer (FDU-7003, Kyeonggi-do, Korea). First, the nanosuspension 
was poured into ampoules and prefrozen in a deep freezer at–40 °C 
for 24 h (model FDU-7003, korea), then the ampoules were 
transferred to glass flasks, and the flask was attached to the vacuum 
adapter of lyophilizer (hetodry winner).  
Optimization of risperidone nanoparticles  
Process yield determination 
The process yield was determined after lyophilization, using the 
following equation:  
% process yield = [Recovered mass/Mass entered into the 
experiment] X100 (Equation 3) 
Risperidone loading efficiency in the dry powders was determined 
by dispersing 1 mg of the lyophilized powder in 10 ml ethanol. The 
obtained suspension was sonicated in a bath-type sonicator for 30 
min and centrifuged at 15,000 rpm for 30 min to remove insoluble 
ingredients. Then, the amount of risperidone in the supernatant was 
determined spectrophotometrically at λmax 276.8 nm. The 
produced mass was devided on the initially added mass of powder 
and calculated as a percent. 
Scanning electron microscopy (SEM) 
The surface morphology of the selected formula (F4) and the pure 
drug was examined by scanning electron microscopy (SEM) (Hitachi 
S800, Japan) at an appropriate magnification after palladium and 
gold coating of the sample. The pictures were taken at an excitation 
voltage of 20 kv. 
Transmission electron microscopy (TEM) 
The high-resolution transmission electron microscope (TEM, JEM-
1400, and Japan) was used to evaluate the surface of the optimized 
formulation (F4) nanosuspension. A drop from the suspension was 
loaded onto a carbon-coated copper grid. The excess suspension was 
removed immediately using filter paper. Negative staining using 
(2%w/v) aqueous solution of phosphotungstic acid was directly 
added to the grid and left for 45 seconds. Then, samples were dried 
for 1 hour. After drying, the grid was directly investigated and 
photographed using (Jeole camera, JEM-1400, Japan) 
Fourier transforms infrared spectroscopy (FTIR) 
The Fourier transforms infrared (FTIR) spectra of pure risperidone 
and nanoparticles (F4) were recorded using FTIR spectro-
photometer. Powders were mixed with potassium bromide 
(spectroscopic grade) and compressed into disks using hydraulic 
press before scanning from 5000 to 500 cm-1. 
Differential scanning calorimetry (DSC)  
The pure risperidone and risperidone nanoparticles (4-6 mg) were 
sealed in the flat-bottomed aluminum pan of the differential scanning 
calorimeter (Shimadzu DSC-50, Japan). Data collection was carried out 
at a temperature range of 0–300 °C, and the heating rate was 5 °C/min 
under nitrogen gas at a flow rate of 25 ml/min. The transition and 
melting point measurements were assessed using the device software.  
X-ray powder diffractometry studies 
The X-ray diffraction pattern of the prepared formula was compared 
to that of the plain drug. Pure risperidone and risperidone 
nanoparticles (F4) were exposed to Cu kα radiation at a voltage of 
45 kV and a current of 40 mA at a rate of 8 deg/min. A fixed slit 
system was employed with following slit parameters: divergence 1o, 
scatter 1o and receiving 0.3 mm. A sample equivalent to 60 mg was 
placed in sample holder groove and tightly packed [19]. 
In vivo drug absorption study 
Selection of animals 
Twelve albino male rabbits, weighing between 2.5 and 3 kg, were 
used in the in vivo study and were divided into two groups, each 
containing 6 rabbits. Based on the previous results (F4) was selected 
for the in vivo study. Animals were acclimatized to laboratory 
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conditions for at least 7 d prior to the study. They were housed 
individually in stainless steel cages, fed a commercial laboratory 
rabbit diet, and allowed water and libitum. The rabbits were fasted 
for overnight (>12 h) prior to dose administration. Animals were 
held in rabbit restrainers during blood sampling, and they were 
conscious throughout the duration of the experiments. The tested 
formulae were orally administered to rabbits as follow: The tablets 
were crushed and suspended in water then giving a certain volume 
of the suspension corresponding to the required dose orally to each 
rabbit using a bulb syringe. Group, I took the Risperdal® tablets 2 
mg; Janssen-Cilag (reference) and group II took the nanoparticles 
(F4) at a dose of 0.2 mg/Kg of the body weight [20]. Each 
preparation was dispersed into 1 ml of distilled water overtaxing for 
20 seconds immediately prior to dosing.  
Blood samples 
Blood samples (0.5 ml) were collected after the administration of 
the drug from the marginal ear vein of the rabbits at time intervals of 
0.5, 1, 1.5,2, 3, 4, 6, 8, 10, 12 and 24 h after drug administration. The 
blood samples were then centrifuged at 3000 rpm for 10 min, and the 
clear plasma was then collected in polyethylene capped tubes and 
deep frozen at-20 °C till required for extraction and analysis.  
Chromatographic conditions 
Analysis of samples was performed using a Shimadzu HPLC system 
equipped with the spectrofluorometric detector. Samples were directly 
injected into HPLC C18 column. (3.9 mm X 300 mm, particle size 5 Â µm), 
the mobile phase was a mixture of methanol and 0.02 N acetic acid 
(40:60 V/V). The pH of the mobile phase was adjusted to 6 with 30% 
acetic acid. After filtration through a membrane filter, the mobile phase 
was degassed and pumped at flow rate 1 ml/min and the UV detector 
was adjusted at 277 nm. A calibration curve was plotted for risperidone 
in the range of 30–300 ng/ml. Duloxetine was used as internal standard, 
and the element peaks were investigated using peak height ratio; all 
assays were performed at ambient condition. 
Pharmacokinetic data analysis 
The Cmax and Tmax were calculated using the plasma concentration-
time curve in the WinNonlinTM Nonlinear Estimation Program. One 
way analysis of variance was employed to assess the significance of 
the difference between the Tmax,  Cmax, AUC(0-24), Kel and MRT data 
from the tested nanoparticles formulation (F4) and the reference at 
a level (p<0.05) using the SPSS program [21].  
Kel: the elimination rate constant was calculated from the negative 
slope of the log-linear terminal portion of the plasma concentration-
time curve. The level of absorption from the nanoparticles formulation 
(F4) relative to the reference was calculated as the relative 
bioavailability by using the formula[22]; Relative bioavailability (%) = 
(AUC (0–24) test/AUC (0-24) reference) x 100 (equation 4)  
RESULTS AND DISCUSSION 
Particle size and poly dispersity index (PDI) 
The choice of suitable stabilizers and the concentration of it are the 
key factors to control the size and stability of the nanosuspension 
during nanoprecipitation process [23, 24] in this study; two stabilizers 
were examined at different concentration (table 1). The results 
showed reduced with the increasing of pluronic F127 concentration as 
the particle size of formula F1 which contains 0.1% pluronic  F127 was 
611.45±46.45 nm compared with 215.56±12.65 nm for F4 which 
contains 0.8% pluronic F127 (table 2). This could be attributed to the 
increase in the molar substitution ratio   (MSR) of the polymer per 
drug. The increase of the hydrophilic corona surrounding the 
polymer to protect the nanoparticles enhances the stability and 
prevents particles from coalescence and preventing aggregation [25, 
26]. On the other hand, the particle size increased with the high 
concentration of PVP K30 which might be due to the higher viscosity 
of the resulting solution that might hinder particle attrition at the 
same milling energy. moreover Ostwald ripening might cause 
agglomeration, and consequently, higher particle size values 
resulted [27] and this has been explained theoretically by Kablanov 
et al. [28]. On the other side, the poly dispersity index (PI) values 
were ranged from 0.09-0.512 which indicates acceptable uniformity 
level for most of the preparations [29].  
Zeta potential analysis 
Zeta potential analysis was performed to investigate the surface 
properties and stability of nanosuspension. Zeta potential of the 
prepared was observed between-9.76 to-19.84 (table 2). Zeta 
potential of risperidone nanosuspensions was relatively low due to 
the shielding effect of the hydrophilic chains of the polymers used. 
These chains formed what is called hydrophilic corona that is 
surrounding the particles and prevent the true measure for the zeta 
potential [30]. On the other hand, the importance of the colloidal 
stability of the nanosuspension is reduced because these formulae 
will be kept in dry state which is reducing the importance of zeta 
potential as a controlling factor. (F4) was found to be-19.84±2.55mV 
(table 2) that concluded that the system had sufficient stability even 
with escalated amounts of pluronic used [31].  
The percent of the total drug content 
The drug content for the prepared formulae was shown in (table 2). 
The drug content for all formulae was calculated as a percent of the 
initially added drug. The amount of the drug within the formulations 
was more than 85 % in all samples. 
  
Table 2: Physicochemical characterization of risperidone nanosuspensions 
Total drug content (%) ZP (mV)±*SD PDI±*SD Particle size (nm) ±*SD Formulation 
86.43 -10.39±1.87 0.512±0.09 604.17±46.45 F1 
92.58 -11.97±1.71 0.154±0.18 523.86±28.41 F2 
91.67 -15.35±2.55 0.271±0.17 313.59±19.58 F3 
94.67 -19.84±2.55 0.198±0.15 215.56±12.65 F4 
90.89 -17.38±2.87 0.336±0.16 638.23±25.64 F5 
92.95 -15.64±4.11 0.09±0.11 441.43±29.26 F6 
87.84 -10.12±2.35 0.158±0.17 491.64±33.45 F7 
91.638 -9.76±3.76 0.501±0.12 611.45±28.08 F8 
PDI-polydispersity index, ZP-Zeta potential, each sample was analysed in triplicate (n = 3) *mean±SD 
 
In vitro dissolution 
The most important feature of nanoparticles is the increase of the 
dissolution rate not only because of increase in surface area but also 
because the use of hydrophilic surfactant. The In vitro dissolution of 
risperidone was carried out for all of the prepared nanosuspensions 
formulations and then compared to that of the pure drug powder 
(fig. 1). The cumulative percentage of the drug dissolved was 98.46 
% at 45 min for selected nanosuspension (F4) while the cumulative 
percentage of the pure drug was 35.52 at 45 min.  The difference 
was significance at p<0.05 when t-test for unpaired data was 
applied, and the release kinetics was found to obey first-order 
kinetics with R2>0.98 (table 3). 
Process yield determination 
The yield of the mass recovered for processed nanoparticle was 
determined after lyophilization process and was considerably high 
(94±2.75%) which indicated efficient processing with minimum batch 
variability, thus representing a negligible loss of drug during 
preparation. 
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Fig. 1 a: In vitro release profile of risperidone F1, F2, F3 and F4 
in phosphate buffer pH 7.4 in comparison to pure risperidone 
 
Fig. 1b: In vitro release profile of risperidone F5, F6, F7 and F8 
in phosphate buffer pH 7.4
 
Table 3: Correlation coefficient R2 values of various kinetic models used for analysis of the release data of risperidone nanosuspension 
Formulation Zero order First order Higuchi diffusion 
F1 0.901 0.981 0.971 
F2 0.885 0.994 0.943 
F3 0.943 0.987 0.953 
F4 0.931 0.985 0.932 
F5 0.899 0.997 0.963 
F6 0.922 0.985 0.981 
F7 0.951 0.982 0.911 
F8 0.969 0.992 0.926 
 
 
Fig. 2: Scanning electron microscopy (SEM), of (a) pure risperidone and (b) risperidone nanoparticles (F4) 
 
 
Fig. 3: Transmission electron microscopy of the optimized formula (F4) nanosuspension with different magnification 
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In order to study the further transformation of selected 
nanosuspension (F4) into solid intermediates and their redispersion 
in water, the suspensions were lyophilized after preparation. The 
morphological characteristics were investigated using scanning 
electron micrographs (SEM). The SEM image of the drug and 
nanosuspension showed a significant difference in the morphology 
of these particles. Nanosuspension sample was appeared to be 
spherical with the mean particle size of 215 nm. They are having 
narrow distribution index (fig. 2b), while SEM of the drug showed 
coarse, irregular, more elongated, and within a micro range (fig. 2 a).  
A close up look for the surface of F4 was carried out using the TEM (fig. 
3) to determine the thickness of Pluronic 127 layer that adsorbed onto 
the surface of the nanoparticles. The results showed the formation of 
uniform non-aggregated particles that adsorb the hydrophilic corona 
around them. Two distinct layers are shown, where the hydrophobic 
part of the polymer is directed inward the particles and the 
hydrophilic part of the polymers are directed outward. 
Fourier transform infrared spectroscopy (FTIR) 
Risperidone spectrum showed a prominent band at 3058.1 cm-1 
corresponding to the aromatic C–H stretching, 2757.1 cm-1 band due 
to aliphatic C–H stretching and a prominent band at 1651.6 cm-1 
corresponds to C=O stretching of the aryl acids (fig. 4). The IR 
spectra of nanoparticles (F4) showed the characteristic peaks of 
risperidone, and this suggested that there was no change in the 
risperidone chemical structure during processing.  
 
 
Fig. 4: Fourier transforms infrared spectroscopy (FTIR):(a) pure 
risperidone, (b) nanoparticles (Lyophilized nanosuspension) 
 
Differential scanning calorimetry (DSC) 
The DSC thermogram of pure risperidone (fig. 5) shows a 
characteristic sharp endothermic melting peak at about 170.12 °C 
with peak onset at 162.91 °C and peak end at 167.17 °C and the heat 
of transition was (15.06 J/g). The thermogram of risperidone 
nanoparticles (F4) shows endothermic melting peak at 155.74 °C 
which is close to the expected value for the drug addition, melting 
enthalpies of endotherm were at a lower-energy state of 4.934 J/g as 
compared to a crystalline form of the drug. The shift in the 
risperidone peak to a lower temperature and the decrease in the 
area of the peak in the nanoparticles compared to pure risperidone 
might be due to smaller risperidone crystals [32]. Additionally, this 
decrease in enthalpy value indicates low lattice energy, and it was 
very well reported that the particles with lower lattice energy are 
easier to dissolve [33].  
 
 
Fig. 5: Differential scanning calorimetry of pure risperidone 
and nanoparticles (lyophilized nanosuspension) 
 
X-ray diffraction (XRD) 
Crystallinity evaluation was carried out using XRD, which was 
carried out to examine the risperidone powder and the 
nanoparticles. The diffraction pattern of risperidone powder 
contained sharp peaks which is indicative of its crystallinity with 
two prominent peaks of high intensity at 2θ =14.21 ° and 2θ =21.25 
(fig. 6 a). The obtained pattern (fig. 6 b) reveal that the drug 
crystallinity of nanosuspension formulation was not affected 
significantly [34], however reduction of the crystallinity was 
observed in the case of the nanosuspension due to the reduction of 
the peak at 14.21 °, suggesting that incorporation of the hydrophilic 
polymers may affect the crystalline state of the drug and gave an 
explanation for the increase in the dissolution rate of it. The data 
show that both freeze drying and sonication process had no 
significant effect on the risperidone nanoparticles. 
 
 
Fig. 6: X-ray diffraction (a) pure risperidone, (b) nanoparticles (lyophilized nanosuspension) 
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In vivo pharmacokinetics study 
A pharmacokinetic study in rabbits proved that the bioavailability 
was enhanced when nanoparticles formulation phenomenon of 
risperidone was compared to the market formula (Risperdal®). 
The mean plasma concentration–time data of risperidone 
following the administration of the marketed Risperdal® (2 mg 
tablets) and formula (F4) is shown in (fig. 7).  
There was a statistically significant difference in the Tmax, Cmax, 
AUC(0-24) and MRT data between the market formula and the 
nanoparticles (F4). The Cmax value of risperidone nanoparticles 
was significant (p<0.05) higher than market formulation (table 4). 
The AUC (0-24) value of risperidone nanoparticles after oral 
administration was almost 2 folds higher than those obtained of 
the marked formulation. 
  
Table 4: Pharmacokinetic parameters after oral administration of risperidone formulations to rabbits (n =6) 
Pharmacokinetic parameters Formulations 
Marketed formulation (Risperdal®) Nanoparticles (F4) 





Tmax (h) 2.83±0.718 1.833±0.389  
AUC(0-24) (ng. h/ml) 243.5±59.72 472.87±86.98  
% Relative Bioavailability - 194.61 % 
Kel (h-1) 0.143±0.09 0.113±0.08 
MRT (h) 8.93±3.63  12.55±2.88 
*Data expressed as mean±standard deviation, Kel–Elimination rate constant, MRT-mean resident time 
 
 
Fig. 7: Plasma concentration of risperidone following the 
administration of Risperidal®tablets and risperidone 
nanoparticles (F4), (n=6±SD) 
 
CONCLUSION 
Nanoprecipitation method was successfully employed to produce stable 
risperidone nanosuspension by using the proper stabilizer (pluronic F 
127). It has been concluded that the nanosuspensions were easily 
formulated and recovered to form nanoparticles. The dissolution was 
significantly enhanced in the prepared nanosuspension. Consequently, 
risperidone nanoparticles represent promising new drug formulation for 
oral drug delivery with enhancement the oral absorption. 
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